Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

NCT04723303 | Completed Early Phase 1 DMC FDA Drug

• 3 other identifiers: DM/PM V2.0IRB201903442OCR33722
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This study will investigate Umbilical Cord Lining Stem Cells (ULSC) as an investigational medicinal product and its use in patients with polymyositis (PM) or dermatomyositis (DM) to see if a single intravenous (IV) infusion of allogeneic umbilical cord lining stem cells (ULSC) safe, tolerable, and feasible to administer.

Conditions

Polymyositis; Dermatomyositis

Outcome Measures

Primary Outcomes (1)

• Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.

  Dose Limiting Toxicities are treatment-emergent suspected adverse reactions graded severe, such as severe infusion-related hypersensitivity toxicities of grade ≥3, and any serious adverse event (SAE). (Note: DLT during an infusion will stop that infusion in that subject.)

  Within 24 hours

Study Arms (1)

Treatment Arm

EXPERIMENTAL

A single IV infusion of ULSC's in patients with DM or PM

Drug: Umbilical Cord Lining Stem Cells

Interventions

Umbilical Cord Lining Stem Cells DRUG

An IV infusion of ULSCs will be administered.

Treatment Arm

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult, male or female, age ≥18 years old
• Diagnosis of definite or probable DM or PM, according to the criteria of Bohan and Peter
• Patients with PM will either be positive for a myositis-associated antibody or have undergone evaluation to exclude mimics, as deemed appropriate by the Investigator (See Note below).
• Signs informed consent.

You may not qualify if:

• Non immune myopathies.
• Cancer associated myositis.
• Hypersensitivity to study product components. History of hypersensitivity to dimethyl sulfoxide (DMSO).
• Pregnant or lactating women.
• Concomitant severe cardiac, pulmonary disease, active infection or other conditions that preclude assessment of safety and efficacy of the study product.
• Patients with predominant muscle atrophy secondary to uncontrolled or chronic DM or PM, based on clinical, biochemical, and/or radiologic assessment, despite previous optimized treatment.
• Anticipated need for surgery during the trial period.
• A history of prevalent noncompliance with medical therapy.
• Recipient of an organ transplant.
• Neutropenia (absolute neutrophil count\<1,800/mm3 \[or \<1,000/mm3 in African-American subjects\]).
• Severe impairment in renal function (estimated glomerular filtration rate \<30 ml/kg\*min).
• Recent or planned use of vaccination with live attenuated viruses.
• Active cancer or prior diagnosis of cancer within the past 2 years (patients with basal and squamous cell cancer of skin will not be excluded).
• Condition that would impair an assessment of muscle strength, including neurological disorders such as Parkinson's disease or severe musculoskeletal condition.
• Any other condition that, in the judgment of the Investigator or Sponsor, would be a contraindication to enrollment, study product administration, or follow-up.

Sponsors & Collaborators

• University of Florida: lead
• Restem, LLC.: collaborator

Study Sites (1)

University of Florida

Gainesville, Florida, 32610, United States

Location

MeSH Terms

Conditions

Polymyositis; Dermatomyositis

Condition Hierarchy (Ancestors)

Myositis; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Study Officials

• Carl Pepine, MD

  University of Florida

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Study Participants will be assigned to one of 3 doses of stem cells depending on when the subject is enrolled. The first three patients will be assigned to the low dose group, the next three patients will be assigned the intermediate dose group and last three patients will receive the high dose of ULSC's. An independent review group will evaluate the response to therapy to each dose group before moving to the next dose. The groups and doses are described below: A low dose group receives an IV infusion of 50 million stem cells. An intermediate dose group receives an IV infusion of 100 million stem cells. A high dose group receives an IV infusion of 200 million stem cells.

Study Record Dates

• First Submitted: December 8, 2020
• First Posted: January 25, 2021
• Study Start: October 6, 2021
• Primary Completion: December 12, 2023
• Study Completion: March 8, 2024
• Last Updated: January 24, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)